Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AMETEK, Inc. (AME) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance

AMETEK, Inc.Trade
Citius Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

AMETEK, Inc. vs Citius Pharmaceuticals Inc — how do they compare? AMETEK, Inc. trades at $259.52 (market cap $58.76B), while Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M). The key difference: AMETEK, Inc. is far larger — about 2936.5× Citius Pharmaceuticals Inc's market cap, and AMETEK, Inc. pays a 0.53% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

AMECTXR
Market Cap
$58.76B$20.01M
Sector
IndustrialsHealth
52-Week High
$256.30$1.82
52-Week Low
$179.28$0.48
Enterprise Value
$60.30B$16.23M
Dividend Yield
0.53%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AMETEK, Inc.

AME trades at $258.62, up 2.27% today, with a bullish technical signal and strong earnings momentum after beating Q2 2026 EPS estimates. The company reported record Q2 results and raised full-year guidance, supported by robust revenue growth and a 20.04% net income margin. Analysts maintain a consensus buy rating with a $281.86 price target, reflecting optimism about its 3D printing and electronics testing segments.

The outlook is positive given consistent earnings beats and upward guidance, but risks include high valuation multiples (P/E 37.47) and exposure to macroeconomic volatility. Institutional sentiment remains strong, with no sell ratings among 30 analysts, though the stock's proximity to resistance at $261 warrants caution for near-term entries.

Citius Pharmaceuticals Inc

CTXR is trading at $0.765, up 13.0% in the past 24 hours, with a bullish technical signal from moving averages. The company shows strong analyst support with 83% buy ratings but faces significant financial challenges including negative earnings, a -823.34% net income margin, and consecutive quarterly EPS misses. Recent news highlights expansion of LYMPHIR cancer treatment commercialization with 78% quarterly growth in new institutional accounts.

While technical indicators suggest near-term upside potential and analyst sentiment remains positive, fundamental weaknesses including substantial losses and negative cash flow from operations present significant investment risks. The company's ability to achieve profitability through its oncology drug commercialization will determine long-term shareholder value creation.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AMETEK, Inc.

Ametek is a diversified industrial conglomerate with over $6 billion in sales. The firm operates through an electronic instruments group and an electromechanical group. EIG designs and manufactures differentiated and advanced instruments for the process, aerospace, power, and industrial end markets. EMG is a focused, niche supplier of highly engineered automation solutions, thermal management systems, specialty metals, and electrical interconnects, among other products. About half of the firm's sales are made in the United States. The firm's asset-light strategy in place for nearly two decades emphasizes growth through acquisitions, new product development through research and development, driving operational efficiencies, and global and market expansion.

Read more on AME

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR